Anti‑vascular endothelial growth factor (anti‑VEGF) agents including Bevacizumab,
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm
shift in the management of various retinal diseases such as diabetic macular edema,
neovascular age‑related macular degeneration (AMD), and retinal vein occlusions. These
together constitute majority of the retinal causes of vision impairment. Nonetheless, patients
usually need multiple and frequent dosing of these agents that cause increased financial …